Advertisement

Cannabinoids pp 599-625 | Cite as

Cardiovascular Pharmacology of Cannabinoids

  • P. Pacher
  • S. Bátkai
  • G. Kunos
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 168)

Abstract p]Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including lcardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in vivo are complex and may involve modulation of autonomic outflow in both the central and peripheral nervous systems as well as direct effects on the myocardium and vasculature. Although several lines of evidence indicate that the cardiovascular depressive effects of cannabinoids are mediated by peripherally localized CB1 receptors, recent studies provide strong support for the existence of as-yet-undefined endothelial and cardiac receptor(s) that mediate certain endocannabinoid-induced cardiovascular effects. The endogenous cannabinoid system has been recently implicated in the mechanism of hypotension associated with hemorrhagic, endotoxic, and cardiogenic shock, and advanced liver cirrhosis. Furthermore, cannabinoids have been considered as novel antihypertensive agents. A protective role of endocannabinoids in myocardial ischemia has also been documented. In this chapter, we summarize current information on the cardiovascular effects of cannabinoids and highlight the importance of these effects in a variety of pathophysiological conditions.

Keywords

Cannabinoid Anandamide CB1 receptor Blood pressure Cardiac function Vascular Ischemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency andmetabolic stability. J Med Chem 37:1889–1893PubMedCrossRefGoogle Scholar
  2. Adams MD, Chait LD, Earnhardt JT (1976) Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat. Br J Pharmacol 56:43–48PubMedGoogle Scholar
  3. Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK (1977) A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia 33:1204–1205PubMedCrossRefGoogle Scholar
  4. Archer RA (1974) The cannabinoids: therapeutic potentials. Annu Rep Med Chem 9:253–259PubMedGoogle Scholar
  5. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbascheck R, Garcia N Jr, Sanyal AJ Kunos G (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7:827–832PubMedGoogle Scholar
  6. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Offertáler L, Bukoski RD, Kunos G (2003) Endocannabinoids are involved in regulating cardiovascular function in spontaneously hypertensive rats. Hypertension 42:A263Google Scholar
  7. Bátkai S, Pacher P, Járai Z, Wagner JA, Kunos G (2004a) Cannabinoid antagonist SR141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287:H595–H600PubMedGoogle Scholar
  8. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G (2004b) Endocannabinoids acting at CB1 receptors regulate cardiovascular function in hypertension. Circulation 110(14):1996–2002PubMedGoogle Scholar
  9. Begg M, Baydoun A, Parsons ME, Molleman A (2001) Signal transduction of cannabinoid CB1 receptors in a smooth muscle cell line. J Physiol 531:95–104PubMedCrossRefGoogle Scholar
  10. Begg M, Mo FM, Offertaler L, Bátkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G (2003) G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem 278:46188–46194PubMedCrossRefGoogle Scholar
  11. Benowitz NL, Jones RT (1975) Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 18:287–297PubMedGoogle Scholar
  12. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB (1998) Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 64:S15–22PubMedGoogle Scholar
  13. Birmingham MK (1973) Reduction by 9-tetrahydrocannabinol in the blood pressure of hypertensive rats bearing regenerated adrenal glands. Br J Pharmacol 48:169–171PubMedGoogle Scholar
  14. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852PubMedCrossRefGoogle Scholar
  15. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G Wagner JA (2003) Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41:657–664PubMedCrossRefGoogle Scholar
  16. Bouchard JF, Lepicier P, Lamontagne D (2003) Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72:1859–1870PubMedCrossRefGoogle Scholar
  17. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled receptor in mouse brain. Mol Pharmacol 60:155–163PubMedGoogle Scholar
  18. Bukoski RD, Bátkai S, Járai Z, Wang, Y, Offertáler L, Jackson WF, Kunos G (2002) CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. Hypertension 39:251-257Google Scholar
  19. Calignano A, La Rana G, Beltramo M, Makriyannis A, Piomelli D (1997) Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol 337:R1–R2PubMedCrossRefGoogle Scholar
  20. Carruba MO, Bondiolotti G, Picotti GB, Catteruccia N, Da Prada M (1987) Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. Eur J Pharmacol 134:15–24PubMedCrossRefGoogle Scholar
  21. Chataigneau T, Feletou M, Thollon C, Villeneuve N, Vilaine J-P, Duhault J, Vanhoutte PM (1998) Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol 123:968–974PubMedGoogle Scholar
  22. Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM (1999) The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol (Lond) 520:539–550PubMedCrossRefGoogle Scholar
  23. Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 132:1281–1291PubMedCrossRefGoogle Scholar
  24. Crawford WJ, Merritt JC (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17:191–196PubMedGoogle Scholar
  25. Darker IT, Millns PJ, Selbie L, Randall MD, S-Baxter G, Kendall DA (1988) Cannabinoid (CB1) receptor expression is associated with mesenteric resistance vessels but not thoracic aorta in the rat. Br J Pharmacol 125, 95PGoogle Scholar
  26. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100:1538–1546PubMedCrossRefGoogle Scholar
  27. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedGoogle Scholar
  28. Di Filippo C, Rossi F, Rossi S, DAmico M (2004) Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 75:453–459PubMedGoogle Scholar
  29. Di Marzo V, Bisogno T, Melck D, Ross R, Brockie H, Stevenson L, Pertwee R, De Petrocellis L (1998) Interactions between synthetic vanilloids and the endogenous cannabinoids system. FEBS Lett 436:449–454PubMedGoogle Scholar
  30. Ellis EF, Moore SF, Willoughby KA (1995) Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 269:H1859–H1864PubMedGoogle Scholar
  31. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 393:231–235PubMedCrossRefGoogle Scholar
  32. Fimiani C, Mattocks D, Cavani F, Salzet M, Deutsch DG, Pryor S, Bilfinger TV, Stefano GB (1999) Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal 11:189–193PubMedCrossRefGoogle Scholar
  33. Fleming I, Schermer B, Popp R, Busse R (1999) Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126:949–960PubMedCrossRefGoogle Scholar
  34. Ford WR, Honan SA, White R, Hiley CR (2002) Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilator responses in rat isolated hearts. Br J Pharmacol 135:1191–1198PubMedCrossRefGoogle Scholar
  35. Fulton DJ, Quilley J (1998) Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. J Pharmacol Exp Ther 286:1146–1151PubMedGoogle Scholar
  36. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61PubMedCrossRefGoogle Scholar
  37. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61:PL191–197CrossRefGoogle Scholar
  38. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR (1999) Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol266:H2085–H2093Google Scholar
  39. Godlewski G, Malinowska B, Schlicker E (2004) Presynaptic cannabinoid CB1 receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol 142:701–708PubMedCrossRefGoogle Scholar
  40. Grainger J, Boachie-Ansah G (2001) Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134:1003–1012PubMedCrossRefGoogle Scholar
  41. Hajos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1–4PubMedGoogle Scholar
  42. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98:3662–3665PubMedCrossRefGoogle Scholar
  43. Harris D, McCulloch AI, Kendall DA, Randall MD (2002) Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539:893–902PubMedCrossRefGoogle Scholar
  44. Hiley CR, Ford WR (2003) Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction? Br J Pharmacol 138:1183–1184PubMedCrossRefGoogle Scholar
  45. Hiley CR, Ford WR (2004) Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 79:187–205PubMedGoogle Scholar
  46. Hillard CJ (2000) Endocannabinoids and vascular function. J Pharmacol Exp Ther 294:27–32PubMedGoogle Scholar
  47. Ho WS, Hiley CR (2003) Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138:1320–1332PubMedGoogle Scholar
  48. Holland M, John Challiss RA, Standen NB, Boyle JP (1999) Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle. Br J Pharmacol 128:597–604PubMedCrossRefGoogle Scholar
  49. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 13:420–423PubMedCrossRefGoogle Scholar
  50. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 584:322–328Google Scholar
  51. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028PubMedGoogle Scholar
  52. Ishioka N, Bukoski RD (1999) A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+-induced relaxation. J Pharmacol Exp Ther 289:245–250PubMedGoogle Scholar
  53. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96:14136–14141PubMedGoogle Scholar
  54. Járai Z, Wagner JA, Goparaju SK, Wang L, Razdan RK, Sugiura T, Zimmer AM, Bonner TI, Zimmer A, Kunos G (2000) Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension 35:679–684PubMedGoogle Scholar
  55. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C (2002) Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55:619–625PubMedCrossRefGoogle Scholar
  56. Kanakis C, Pouget JM, Rosen KM (1976) The effects of Δ9-THC (cannabis) on cardiac performance with or without beta blockade. Circulation 53:703–709PubMedGoogle Scholar
  57. Kapoor K, Arulmani U, Heiligers JP, Garrelds IM, Willems EW, Doods H, Villalon CM, Saxena PR (2003) Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 140:329–338PubMedCrossRefGoogle Scholar
  58. Kosersky DS (1978) Antihypertensive effects of delta9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 233:76–81PubMedGoogle Scholar
  59. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG, Stephano GB (2001) Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131:523–525PubMedCrossRefGoogle Scholar
  60. Krylatov AV, Bernatskaia NA, Maslov LN, Pertwee RG, Mechoulam R, Stefano GB, Sharaevskii MA, Sal’nikova OM (2002a) Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors. Ross Fiziol Zh Im I M Sechenova 88:560–567PubMedGoogle Scholar
  61. Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, Pertwee RG, Sal’nikova OM, Stefano JB, Lishmanov Y (2002b) Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med 133:122–124PubMedCrossRefGoogle Scholar
  62. Krylatov AV, Uzhachenko RV, Maslov LN, Ugdyzhekova DS, Bernatskaia NA, Pertwee R, Stefano GB, Makriyannis A (2002c) Anandamide and R-(+)-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors. Eksp Klin Farmakol 65:6–9PubMedGoogle Scholar
  63. Kunos G, Járai Z, Bátkai S, Goparaju SK, Ishac EJ, Liu J, Wang L, Wagner JA (2000) Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108:159–168PubMedGoogle Scholar
  64. Kunos G, Bátkai S, Offertáler L, Mo F, Liu J, Karcher J, Harvey-White J (2002) The quest for a vascular endothelial cannabinoids receptor. Chem Phys Lipids 121:45–56PubMedCrossRefGoogle Scholar
  65. Lagneux C, Lamontagne D (2001) Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132:793–796PubMedCrossRefGoogle Scholar
  66. Lake KD, Compton DR, Varga K, Martin BR, Kunos G (1997a) Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281:1030–1037PubMedGoogle Scholar
  67. Lake KD, Martin BR, Kunos G, Varga K (1997b) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29:1204–1210PubMedGoogle Scholar
  68. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401–404PubMedCrossRefGoogle Scholar
  69. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D (2003) Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139:805–815PubMedGoogle Scholar
  70. Li J, Kaminski NE, Wang DH (2003) Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41:757–762PubMedGoogle Scholar
  71. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346:835–840PubMedGoogle Scholar
  72. Liu J, Bátkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF, Gao B, Kunos G (2003) LPS induces anandamide synthesis in macrophages via CD14/MAPK/PI3 K/NF-kB independently of platelet activating factor. J Biol Chem 278:45034–45039PubMedGoogle Scholar
  73. Lumsden AB, Henderson JM, Kutner MH (1988) Endotoxin levels measured by a chromatographic assay in portal, hepatic and peripheral blood in patients with cirrhosis. Hepatology 8:232–236PubMedGoogle Scholar
  74. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A (2000) Anandamide uptake by human endothelial cells and its regulation by nitric oxide. Biol Chem 275:13484–13492Google Scholar
  75. Malinowska B, Godlewski G, Bucher B, Schlicker E (1997) Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol 356:197–202PubMedGoogle Scholar
  76. Malinowska B, Kwolek G, Gothert M (2001) Anandamide and methanandamide induce both vanilloid VR1-and cannabinoids CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364:562–569PubMedGoogle Scholar
  77. Matsuda LA, Lolait SJ, Brownstein MJ, Young CA, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564PubMedCrossRefGoogle Scholar
  78. Mechoulam R, Fride E, Di Marzo V (1998a) Endocannabinoids. Eur J Pharmacol 359:1–18PubMedCrossRefGoogle Scholar
  79. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M (1998b) Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362:R1–R3PubMedCrossRefGoogle Scholar
  80. Mombouli JV, Schaeffer G, Holzmann S, Kostner GM, Graier WF (1999) Anandamideinduced mobilization of cytosolic Ca2+ in endothelial cells. Br J Pharmacol 126:1593–1600PubMedCrossRefGoogle Scholar
  81. Mukhopadhyay S, Chapnick BM & Howlett AC (2002) Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol 282:H2046–H2054Google Scholar
  82. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65PubMedCrossRefGoogle Scholar
  83. Nahas G, Trouve R (1985) Effects and interactions of natural cannabinoids on the isolated heart. Proc Soc Exp Biol Med 180:312–316PubMedGoogle Scholar
  84. Niederhoffer N, Szabo B (2000) Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 294:707–713PubMedGoogle Scholar
  85. Niederhoffer NB, Szabo B (1999) Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. Br J Pharmacol 126:1383–1386PubMedGoogle Scholar
  86. O’sullivan SE, Kendall DA, Randall MD (2004) Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141:803–812PubMedGoogle Scholar
  87. Offertáler L, Mo FM, Bátkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699–705PubMedGoogle Scholar
  88. Orliac ML, Peroni R, Celuch SM, Adler-Graschinsky E (2003) Potentiation of anandamide effects in mesenteric beds isolated fro mendotoxemic rats. J Pharmacol Exp Ther 304:179–184PubMedCrossRefGoogle Scholar
  89. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virág L, Deb A, Szabo E, Ungvári Z, Wolin MS, Groves JT, Szabo C (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896–904PubMedCrossRefGoogle Scholar
  90. Pacher P, Bátkai S, Kunos G (2004) Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (Lond) 558:647–657PubMedCrossRefGoogle Scholar
  91. Plane F, Garland CJ (1996) Influence of contractile agonists on the mechanism of endothelium-dependent relaxation in rat isolated mesenteric artery. Br J Pharmacol 119:191–193PubMedGoogle Scholar
  92. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB (1998) N-Arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 43:H375–H381Google Scholar
  93. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, Hogestatt ED (2000) Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation tomethanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries.Br J Pharmacol 130:1483–1488PubMedCrossRefGoogle Scholar
  94. Ralevic V, Kendall DA, Randall MD, Smart D (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: Roles in regulation of cardiovascular function. Life Sci 71:2577–2594PubMedCrossRefGoogle Scholar
  95. Randall MD, Kendall DA (1997) Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335:205–209PubMedCrossRefGoogle Scholar
  96. Randall MD, Kendall DA (1998) Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur J Pharmacol 346:51–53PubMedCrossRefGoogle Scholar
  97. Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA (1996) An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229:114–120PubMedCrossRefGoogle Scholar
  98. Randall MD, Harris D, Kendall DA, Ralevic V (2002) Cardiovascular effects of cannabinoids. Pharmacol Ther 95:191–202PubMedCrossRefGoogle Scholar
  99. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, Martin-Ruiz R, Arroyo V, Rivera F, Rodes J, Jimenez W (2002) Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122:85–93PubMedCrossRefGoogle Scholar
  100. Rosenkrantz H, Braude M (1974) Acute, subacute and 23-day chronic marihuana inhalation toxicities in the rat. Toxicol Appl Pharmacol 28:428–441PubMedGoogle Scholar
  101. Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C (1999) Anandamide and WIN55,212-2 inhibit cyclic AMP-formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 11:691–699PubMedCrossRefGoogle Scholar
  102. Schlicker E, Timm J, Zentner J, Gothert M (1997) Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol 356:583–589PubMedGoogle Scholar
  103. Siqueira SW, Lapa AJ, Ribeiro do Valle J (1979) The triple effect induced by delta 9-tetrahydrocannabinol on the rat blood pressure. Eur J Pharmacol 58:351–357PubMedCrossRefGoogle Scholar
  104. Smith PJ, McQueen DS (2001) Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 134:655–663PubMedCrossRefGoogle Scholar
  105. Stein EA, Fuller SA, Edgemond WS, Campbell WB (1996) Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 119:107–114PubMedGoogle Scholar
  106. Szabo B, Nordheim U, Niederhoffer N (2001) Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297:819–826PubMedGoogle Scholar
  107. Szolcsányi J (2000) Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci 21:41–42PubMedGoogle Scholar
  108. Ugdyzhekova DS, Bernatskaya NA, Stefano JB, Graier VF, Tam SW, Mekhoulam R (2001) Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors. Bull Exp Biol Med 131:251–253PubMedCrossRefGoogle Scholar
  109. Ugdyzhekova DS, Krylatov AV, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG (2002) Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 133:125–126PubMedCrossRefGoogle Scholar
  110. Valk PJ, Delwel R (1998) The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Leuk Lymphoma 32:29–43PubMedGoogle Scholar
  111. Varga K, Lake K, Martin BR, Kunos (1995) G Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278:279–283PubMedCrossRefGoogle Scholar
  112. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682–686PubMedGoogle Scholar
  113. Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035–1044PubMedGoogle Scholar
  114. Varma DR, Goldbaum D (1975) Effect of delta9-tetrahydrocannabinol on experimental hypertension in rats. J Pharm Pharmacol 27:790–791PubMedGoogle Scholar
  115. Vidrio H, Sanchez-Salvatori MA, Medina M (1996) Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28:332–336PubMedCrossRefGoogle Scholar
  116. Vizi ES, Katona I, Freund TF (2001) Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol 431:237–244PubMedCrossRefGoogle Scholar
  117. Vollmer RR, Cavero I, Ertel RJ, Solomon TA, Buckley JP (1974) Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol 26:186–192PubMedGoogle Scholar
  118. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390:518–521PubMedGoogle Scholar
  119. Wagner JA, Varga K, Járai Z, Kunos G (1999) Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33:429–434PubMedGoogle Scholar
  120. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, Ertl G (2001a) Endogenous cannabinoidsmediate hypotension after experimentalmyocardial infarction. J Am Coll Cardiol 38:2048–2054PubMedCrossRefGoogle Scholar
  121. Wagner JA, Járai Z, Bátkai S, Kunos G (2001b) Hemodynamic effects of cannabinoids: coronary and cerebal vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423:203–210PubMedCrossRefGoogle Scholar
  122. Wagner JA, Hu K, Karcher J, Bauersachs J, Schafer A, Laser M, Han H, Ertl G (2003) CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138:1251–1258PubMedCrossRefGoogle Scholar
  123. Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141:775–785PubMedCrossRefGoogle Scholar
  124. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, Shimizu H, Matsuo S, Imaizumi H, Maruyama I (2001) Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294:73–82PubMedCrossRefGoogle Scholar
  125. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B (2003) Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424:434–438PubMedGoogle Scholar
  126. White R, Hiley CR (1997) A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122:1573–1584PubMedCrossRefGoogle Scholar
  127. White R, Ho WS, Bottrill FE, Ford WR, Hiley CR (2001) Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 134:921–929PubMedCrossRefGoogle Scholar
  128. Zahner MR, Li DP, Chen SR, Pan HL (2003) Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 551:515–523PubMedCrossRefGoogle Scholar
  129. Zaugg HE, Kyncl J (1983) New antihypertensive cannabinoids. J Med Chem 26:214–217PubMedCrossRefGoogle Scholar
  130. Zygmunt PM, Högestätt ED, Waldeck K, Edwards G, Kirkup AJ, Weston AH (1997) Studies on the effects of anandamide in rat hepatic artery. Br J Pharmacol 122:1679–1686PubMedCrossRefGoogle Scholar
  131. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sorgard M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457PubMedGoogle Scholar
  132. Zygmunt PM, Andersson DA, Högestätt ED (2002) Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22:4720–4727PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • P. Pacher
    • 1
  • S. Bátkai
    • 1
  • G. Kunos
    • 1
  1. 1.Laboratory of Physiologic StudiesNational Institute on Alcohol Abuse and Alcoholism, National Institutes of HealthBethesdaUSA

Personalised recommendations